Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.50 |
| ▸ | CES1 | P23141 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.41 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.41 |
| ▸ | ALB | P02768 | 1/20 | 0.41 |
| ▸ | MYC | P01106 | 2/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ASPH | Q12797 | 1/20 | 0.38 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.38 |
| ▸ | HAAO | P46952 | 1/20 | 0.38 |
| ▸ | GABRP | O00591 | 1/20 | 0.38 |
| ▸ | GABRD | O14764 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29465861 | 1.00 | CES2 (0.50) | CES2CES1CYP1A2MAP2K1MAP2K2 | |
| SCHEMBL14472134 | 0.84 | CYP1A2 (0.44) | CES2CES1CYP1A2ALBMYC | |
| SCHEMBL26771502 | 0.83 | CES2 (0.52) | CES2CES1MAP2K1MAP2K2MYC | |
| SCHEMBL109592 | 0.83 | CLCN2 (0.45) | CES2CES1CYP1A2MAP2K1ALB | |
| SCHEMBL31158853 | 0.83 | CLCN2 (0.45) | CES2CES1CYP1A2MAP2K1ALB | |
| SCHEMBL1192063 | 0.83 | CES2 (0.45) | CES2CES1CYP1A2MAP2K1MAP2K2 | |
| SCHEMBL30367318 | 0.83 | HPGD (0.44) | CYP1A2MYCADRA2ACLCN2TSHR | |
| SCHEMBL7822093 | 0.83 | HPGD (0.44) | CYP1A2MYCADRA2ACLCN2TSHR | |
| SCHEMBL26771499 | 0.83 | CES2 (0.50) | CES2CES1HDAC4TSHRBCHE | |
| SCHEMBL23243439 | 0.81 | CES2 (0.48) | CES2CES1MAP2K1MAP2K2HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 201 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122059801-A | Synthesis method of Marbalol Sha Wei side chain intermediate | 重庆圣华曦药业股份有限公司 | 2026-05-19 | — | — | CN | claimed |
| CN-112858534-A | HPLC detection method for baroxavir ester intermediate and related substances thereof | 山东新华制药股份有限公司 | 2021-05-28 | — | — | CN | claimed |
| CN-110790690-A | Synthetic method of 3, 4-difluoro-2- ((phenylthio) methyl) benzoic acid | 湖南师范大学 | 2020-02-14 | — | — | CN | claimed |
| EP-1514864-B1 | Difluoralkyl aromatic compounds | SALTIGO GMBH (DE) | 2008-03-19 | — | — | EP | claimed |
| EP-1514864-A2 | Difluoralkyl aromatic compounds | Bayer Chemicals AG (DE) | 2005-03-16 | — | — | EP | claimed |
| US-20050054733-A1 | Difluoroalkylaromatics | LANXESS DEUTSCHLAND GMBH (DE) | 2005-03-10 | — | — | US | claimed |
| CN-122059801-A | Synthesis method of Marbalol Sha Wei side chain intermediate | 重庆圣华曦药业股份有限公司 | 2026-05-19 | — | — | CN | disclosed |
| CN-122059801-A | Synthesis method of Marbalol Sha Wei side chain intermediate | 重庆圣华曦药业股份有限公司 | 2026-05-19 | — | — | CN | disclosed |
| EP-4692092-A1 | NOVEL COMPOUNDS WITH MTORC2-INHIBITORY ACTIVITY AND USES THEREOF | Aliad Biopharma (KR) | 2026-02-11 | — | — | EP | disclosed |
| US-12544448-B2 | C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors | Revolution Medicines, Inc. (US) | 2026-02-10 | — | — | US | disclosed |
| US-20250263399-A1 | CBL-B MODULATORS AND USES THEREOF | SCHRÖDINGER, INC. | 2025-08-21 | — | — | US | disclosed |
| US-12325697-B2 | CBL-B modulators and uses thereof | NIMBUS CLIO, INC. (US) | 2025-06-10 | — | — | US | disclosed |
| US-20250108117-A1 | C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2025-04-03 | — | — | US | disclosed |
| EP-0609798-B1 | 4-Benzoyl isoxazoles and their use as herbicides | AVENTIS AGRICULTURE LTD (GB) | 2002-10-02 | — | — | EP | disclosed |
| EP-0625505-B1 | 2-Cyano-1,3-dione derivatives and their use as herbicides | RHONE POULENC AGRICULTURE (GB) | 1998-10-28 | — | — | EP | disclosed |
| EP-0759911-A1 | 4-BENZOYLISOXAZOLE DERIVATIVES AND THEIR USE AS HERBICIDES | RHONE POULENC AGRICULTURE LTD. (GB) | 1997-03-05 | — | — | EP | disclosed |
| WO-1995031446-A1 | 4-BENZOYLISOXAZOLE DERIVATIVES AND THEIR USE AS HERBICIDES | RHONE POULENC AGRICULTURE LTD. (GB) | 1995-11-23 | — | — | WO | disclosed |
| US-5374606-A | Pre- and postemergence | RHONE-POULENC AGRICULTURE LIMITED (GB) | 1994-12-20 | — | — | US | disclosed |
| EP-0625505-A2 | 2-Cyano-1,3-dione derivatives and their use as herbicides | RHONE POULENC AGRICULTURE LTD. (GB) | 1994-11-23 | — | — | EP | disclosed |
| EP-0609798-A1 | 4-Benzoyl isoxazoles and their use as herbicides | RHONE POULENC AGRICULTURE LTD. (GB) | 1994-08-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250108117-A1 | C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors | MTOR, RICTOR, RPTOR | CES2 3830/4885CES1 3116/4885CYP1A2 4804/4885 |
| US-20250263399-A1 | CBL-B MODULATORS AND USES THEREOF | CBLB, CBL, CBLC | CES2 3737/4885CES1 2390/4885CYP1A2 4603/4885 |
| US-20050054733-A1 | Difluoroalkylaromatics | NQO1, TYR, FLI1 | CES2 141/4885CES1 961/4885CYP1A2 88/4885 |
| US-12325697-B2 | CBL-B modulators and uses thereof | CBLB, CBL, CBLC | CES2 3737/4885CES1 2390/4885CYP1A2 4603/4885 |
| US-12544448-B2 | C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors | RICTOR, MTOR, MLST8 | CES2 4188/4885CES1 3902/4885CYP1A2 2040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.